Diligence memo · auto-generated · as of July 2, 2026
Yaupon Therapeutics Inc
Yaupon Therapeutics Inc looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Yaupon Therapeutics Inc operates in Pharmaceuticals, based in MALVERN.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Yaupon Therapeutics Inc has raised $22M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $8.3M on 2012-05-14.
Most recent recorded round closed around 2012-05-14.
Valuation (modeled)modeled
Provath models Yaupon Therapeutics Inc at approximately $257M (range $9.5M–$1.4B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.42× the median modeled value of Series A Pharmaceuticals companies in 2010–2012 (57 peers) — value vs value, same stage and era. Within the normal band (142% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 11 months.
Last raise 14.1 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 1.0× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 67% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 72% of those peers.
Closest niche peers: Satori Pharmaceuticals Inc, Labrys Biologics, Inc., Telsar Pharma, Inc., Acetylon Pharmaceuticals, Inc., Seldar Pharma, Inc..
Peoplefiled
20 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.